SNPMiner Trials (Home Page)
Report for SNP rs11200638
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There are 6 clinical trials
Clinical Trials
1 LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population
This study is to investigate whether variants in the LOC387715 locus and the HtrA serine peptidase 1 (HTRA1) gene within the 10q26 locus are associated with polypoidal choroidal vasculopathy and whether they are associated with clinical patterns including angiographic phenotype in a Korean population.
NCT01108250 Age-Related Macular Degeneration Genetic: LOC387715/HTRA1 genotyping MeSH: Macular Degeneration
One hundred Korean patients with polypoidal choroidal vasculopathy and 100 control subjects were genotyped for the LOC387715 (rs10490924) and the HTRA1 gene polymorphism (rs11200638)
Primary Outcomes
Description: to investigate whether variants in the LOC387715 locus and the HtrA serine peptidase 1 (HTRA1) gene within the 10q26 locus are associated with polypoidal choroidal vasculopathy (PCV)
Measure: Genotyping of LOC387715/HTRA1 of PCV and control groups Time: 4weeksSecondary Outcomes
Description: The association of the risk allele of the LOC387715/HTRA1 and indocyanine angiographic characteristics of polypoidal choroidal vasculopathy including subretinal hemorrhage, pigment epithelial detachment, and serous retinal detachment.
Measure: Indocyanine angiographic findings of polypoidal choroidal vasculopathy Time: 20 minutesDescription: To evaluate the association between visual acuity and genotype of polypoidal choroidal vasculopathy
Measure: Visual acuity using Snellen chart Time: 2 x 5 minutes2 LOC387715/HTRA1 Variants and the Response to Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy
This study is to investigate whether there is an association of the LOC387715/HTRA1 variants with response to treatment with combined photodynamic therapy and intravitreal bevacizumab for patients with polypoidal choroidal vasculopathy.
NCT01233115 Age-Related Macular Degeneration MeSH: Macular Degeneration
Patients were genotyped for the LOC387715 (rs10490924) and the HTRA1 gene polymorphism (rs11200638).
Primary Outcomes
Description: Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA up to 12 months
Measure: Best-corrected visual acuity Time: up to 12 monthsSecondary Outcomes
Description: Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany) was evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA.
Measure: Angiographic characteristics Time: up to 12 months3 Association of Vascular Endothelial Growth Factor and LOC387715/HTRA1 Polymorphisms With the Response to Intravitreal Ranibizumab Injections in Polypoidal Choroidal Vasculopathy
This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injections for patients with polypoidal choroidal vasculopathy.
NCT01233128 Age-Related Macular Degeneration MeSH: Macular Degeneration
Patients were genotyped for the LOC387715 (rs10490924), HTRA1 gene (rs11200638), and VEGF (rs3025039 and rs833069)polymorphism using Real-Time polymerase chain reaction.
Primary Outcomes
Description: Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA before treatment and BCVA up to 12 months.
Measure: Best-corrected visual acuity Time: up to 12 monthsSecondary Outcomes
Description: Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany)were evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA.
Measure: Angiographic characteristics Time: up to 12 months4 Genetic Assessment of Early to Late macuLar dEgeneration studY 2
The purpose of this study is to determine if polymorphisms at rs11200638 on HTRA1 and rs1061170 on CFH are associated with an accelerated progression to advanced AMD (wet AMD or GA) in patients with early AMD (soft confluent drusen>120 microns ) in the study eye, and with either early AMD or advanced AMD in the non-study eye.
NCT01464710 Age-related Macular Degeneration MeSH: Macular Degeneration
Genetic Assessment of Early to Late macuLar dEgeneration studY 2. Genetic Assessment of Early to Late Macular Degeneration Study The purpose of this study is to determine if polymorphisms at rs11200638 on HTRA1 and rs1061170 on CFH are associated with an accelerated progression to advanced AMD (wet AMD or GA) in patients with early AMD (soft confluent drusen>120 microns ) in the study eye, and with either early AMD or advanced AMD in the non-study eye.
Primary Outcomes
Measure: To determine the allele frequency for patients that progress to bilateral advanced AMD in the study eye Time: 5 yearsSecondary Outcomes
Measure: To determine the allele frequency for patients that do not progress to bilateral advanced AMD in the study eye. Time: 5 years5 A Multicenter Study on the Investigation of Previously Verified Leading Gene Polymorphisms Related to Age-related Macular Degeneration in Turkish Population
The purpose of this study is to determine whether common genetic polymorphisms that have been verified to be related to age-related macular degeneration (AMD) in some populations are also associated with AMD in Turkish population
NCT02248324 Age-related Macular Degeneration MeSH: Macular Degeneration
The gen variants mostly studied in relation to AMD are CFH (rs1061170 and rs1410996), LOC387715/ARMS-2 (A69S /rs10490924), HTRA-1 (rs11200638), C3 (R102G/ rs2230199), C2 E318D (rs9332739), and CFB R32Q (rs641153).
In the introduced projects study, the relationship of eight different gen polymorphisms (CFH rs1061170 and rs1410996, LOC387715 / ARMS2 gene rs10490924, C2 gene rs9332739, CFB gene rs641153, CFI rs10033900 , HTRA-1 gene rs11200638, C3 rs2230199) will be studied in 2800 patients with high risk intermediate and late stage AMD and 2200 age-matched control subjects.
Primary Outcomes
Description: Gene polymorphisms of 8 region with identification of homozygous, heterozygote and wild type genotyping and alleles
Measure: rate of homozygous, heterozygous or wild type genotype and allels Time: at the end of third yearsSecondary Outcomes
Measure: Odds ratios for each genotyping in healthy elderly controls and patients with age related macular degeneration Time: at the end of third yearsOther Outcomes
Measure: Odds ratios for various combinations of gene regions between healthy elderly control and patients with age related macular degeneration Time: at the end of third years6 The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular Degeneration
Purpose: To examine the genotypes associated with the peripheral retinal phenotypic features in patients with age-related macular degeneration documented with wide-field imaging. Design: Clinic-based case series study in Croatia. Participants: 160 patients >50 years of age known to have early or advanced AMD and 150 subjects >50 years of age without known AMD (controls) Methods: Both groups of patients were examined with ophthalmoscopy and OCT to confirm their classification. Posterior and peripheral fundus features were documented with Optos wide-field imaging (Optos P200MA, Optos Plc, Dunfermline, Scotland) and graded. DNA was extracted from blood samples and gene polymorphisms were evaluated for complement factor H (CFH) rs1061170 and rs1410996, age-related maculopathy susceptibility (ARMS2) rs10490924, high temperature requirement factor A1 (HtrA1) rs11200638, complement factor B (CFB) rs4151667 and rs641153, complement factor 2 (C2) rs9332739 and rs547154 and complement factor 3 (C3) rs2230199.
NCT03492853 Peripheral Retinal Degenerations, Age Related Macular Degeneration Polymorphisms Genetic: DNA extraction and sequencing MeSH: Macular Degeneration Retinal Degeneration
HPO: Retinal atrophy Retinal degeneration
DNA was extracted from blood samples and gene polymorphisms were evaluated for complement factor H (CFH) rs1061170 and rs1410996, age-related maculopathy susceptibility (ARMS2) rs10490924, high temperature requirement factor A1 (HtrA1) rs11200638, complement factor B (CFB) rs4151667 and rs641153, complement factor 2 (C2) rs9332739 and rs547154 and complement factor 3 (C3) rs2230199.
Primary Outcomes
Description: the association between those two parameters
Measure: the association of the peripheral retina changes and genotyping Time: 2 years